The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy ...

D. Boral Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $14 price target Medicus is a development-stage ...

Jessica Zbinden-Webster was diagnosed with a rare kind of basal cell carcinoma when she was just 26, now she campaigns to ...